Gene Therapy’s Next Hotspot? Look to Australia

Oxford Biomedica licenses key platforms to VVMF, boosting gene therapy manufacturing across Asia-Pacific

19 Mar 2026

Gene therapy manufacturing has taken a notable step south. On March 18, 2026, Oxford Biomedica struck a five-year licensing deal with Australia’s Viral Vector Manufacturing Facility, handing VVMF worldwide access to its inAAVate AAV manufacturing platform, with the option to add its LentiVector technology later.

That matters because VVMF is Australia’s only dedicated commercial viral vector CDMO. With the agreement, it gets processes refined over three decades by one of the sector’s best-known players, which could shorten the path to GMP readiness and help meet rising demand for advanced therapies across Asia-Pacific.

For Oxford Biomedica, the appeal is straightforward. The company expands its reach without spending on new bricks and mortar, collecting a low single-digit million upfront license fee plus future payments tied to use. It is another way to monetize its platform business, which already has momentum. OXB’s contracted order book stood at £224 million at the end of 2025, up 20% from a year earlier.

The broader backdrop makes the deal more than a routine licensing arrangement. Asia-Pacific is widely seen as the fastest-growing market for viral vector manufacturing in the years ahead, fueled by more clinical programs, stronger government backing for biotech infrastructure, and growing interest in personalized medicine. That gives Australia a chance to move from outpost to regional hub.

The technology itself is part of the pitch. InAAVate uses a dual-plasmid, suspension-based process designed for scalable AAV production, while LentiVector is built on a fourth-generation lentiviral architecture. Both have already been used in clinical and commercial settings, so VVMF is starting with a tested foundation rather than a blank sheet.

That may be the clearest signal in this deal. Gene therapy manufacturing is no longer being built one facility at a time from scratch. More often, proven platforms are being licensed across borders, cutting development time and raising the standard of production. For patients waiting on therapies still working through the pipeline, that is not just an industry detail. It is the part that counts.